Trial · NCT07445893
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
NCT07445893, Not applicable, Recruiting, Duan Minghui
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV. Trials, record NCT07445893. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07445893
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
- NCT number
- NCT07445893
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Duan Minghui
- Conditions
- Polycythemia Vera (PV)
- Interventions
- Gecacitinib Hydrochloride Tablets；Pegylated interferon alfa-2b
- First posted
- 2026-03-03
- Last updated
- 2026-06-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hematologic remission rate at Week 24 | Week 24 | Simultaneous achievement of HCT \<45%, WBC \<10×10⁹/L, and PLT ≤400×10⁹/L |
| Secondary | HCT remission rate | week 24 | Proportion of patients achieving HCT \<45% at 24 weeks |
| Secondary | Time to HCT remission | Up to 24 weeks | Time from treatment initiation to HCT remission |
| Secondary | Duration of HCT remission | Through study completion, an average of 2 year | Interval from first achievement of HCT remission to reappearance of HCT ≥45% |
| Secondary | Proportion of patients achieving spleen reduction at 24 weeks | Week 4, Week 12, Week 24 | ≥10% shortening of the longest spleen diameter by palpation or normalization of spleen size |
| Secondary | Proportion of patients achieving symptom improvement at 24 weeks | Week 4, Week 12, Week 24 | ≥50% reduction in total symptom score on the MPN Symptom Assessment Form. The MPN-SAF-TSS is used to assess the symptom burden of patients with myeloproliferative neoplasms. The questionnaire also reflects the quality of life of patients to a certain extent. During the diagnosis and treatment process, the MPN-10 questionnaire includes 10 sub symptoms (fatigue, early satiety, abdominal discomfort, poor activity, lack of concentration, night sweats, skin itching, bone pain, fever, and weight loss). Each item is graded from 0 (none) to 10 (heaviest), with a total score of 0-100 points. The higher the total score, the heavier the symptom burden. |
| Secondary | Percentage reduction in JAK2 mutation burden after 24 weeks of treatment | Week 12, Week 24 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07445893
GET https://conductscience.org/api/trials/v1/NCT07445893/registered